Summit Therapeutics Inc.

SMMT

NASDAQ

Healthcare

Biotechnology

Cambridge, MA, US159 employeessummittxinc.com

$19.39

+0.47(2.46%)

Mkt Cap $14.4B

$13.85

$36.70

52-Week Range

At A Glance

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America.

Most recently: as if fully set forth herein. In accordance with General Instruction B.2 of Form 8-K, the information set forth under Item 2.02 and in Exhibit 99.1 shall not be (2026-02-23).

$14.4B

Market Cap

—

Revenue

-$1.1B

Net Income

Employees159

Fundamentals

How The Business Makes Money

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Industry Biotechnology

Activity

What Changed Recently

Financial Results

Feb 22, 2026

as if fully set forth herein. In accordance with General Instruction B.2 of Form 8-K, the information set forth under Item 2.02 and in Exhibit 99.1 shall not be

Financial Results

Jan 11, 2026

and in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or

Other Event

Jan 28, 2026

Other Events. On January 29, 2026, Summit Therapeutics Inc. (the “Company”) issued a press release announcing that the U.S. Food & Drug Administration (“FDA”) h

Peer Companies

Company	Price	Change	Market Cap	P/E
RPRXRoyalty Pharma plc	$48.57	+0.17%	$20.8B	25.6
ROIVRoivant Sciences Ltd.	$28.30	+1.65%	$20.3B	-24.1
EXASExact Sciences Corporatio...	$104.91	+0.00%	$20.0B	-95.7
RVMDRevolution Medicines, Inc...	$99.12	+0.49%	$19.6B	-16.2
MRNAModerna, Inc.	$49.11	-1.84%	$19.4B	-7.1
BBIOBridgeBio Pharma, Inc.	$73.22	-1.65%	$14.2B	-18.8
ASNDAscendis Pharma A/S	$228.84	+0.26%	$14.0B	-50.7
IONSIonis Pharmaceuticals, In...	$74.78	-0.47%	$12.4B	-30.1

Analyst View

Company Profile

CIK0001599298

ISINUS86627T1088

CUSIP86627T108

Phone617 514 7149

AddressOne Broadway, Cambridge, MA, 02142, US

SEC EDGAR